Go to IMDRF first, industry tells FDA on plans to standardize GCP for foreign device trials
This article was originally published in SRA
Efforts by the US Food and Drug Administration to standardize good clinical practice requirements for certain foreign medical device trials have been termed as "premature" by the medtech industry. Device companies believe that the FDA should first collaborate with the International Medical Device Regulators Forum to develop harmonized guidance on this topic instead of straightaway changing its rules on acceptance of data from foreign device trials1-4.
You may also be interested in...
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.